



Cleansing Notice

Melbourne, Australia, 23 October 2024 – InhaleRx Ltd (ASX: IRX), ('IRX' or 'the Company') an Australian healthcare company developing unique inhaled drug-device products to address unmet medical needs in the pain management and mental health sectors, advises that, effective 3 October 2024, it issued 3,444,828 ordinary shares as outlined in the Appendix 2A of that date.

As required by section 708A(6) of the Corporations Act 2001 (Cth) ("Corporations Act"), the Company notifies ASX that:

1. The shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. This notice is being given under section 708A(5)(e) of the Corporations Act;
3. As at the date of this notice, the Company has complied with:
 - a. The provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - b. Section 674 of the Corporations Act; and
4. As at the date of this notice, there is no information that is 'excluded information' (within the meaning of section 708A(7) and 708A(8) of the Corporations Act).

Authorised by the Board of Directors.

For further information:

www.inhalerx.com.au

James Barrie, Company Secretary

Phone +61 3 8678 4091

About InhaleRx Limited (ASX: IRX) – www.inhalerx.com.au

InhaleRx Limited is an Australian healthcare company which is developing unique medicinal drug-device products to address unmet medical needs in pain management and mental health sectors.

The overarching goal is to pursue U.S. FDA approval and registration using rapid and cost-effective regulatory pathways, such as 505(b)(2).

There is a significant economic opportunity for IRX and the Company's shareholders, the first medical indications under investigation are Breakthrough Cancer Pain (BTcP) and Panic Disorder (PD), both of which currently have limited safe and effective treatment options.

IRX holds an innovation patent and provisional patents for the nominated indications and the Company plans to continue to strengthen this position.